COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01642862
Recruitment Status : Terminated (Low recruitment rate)
First Posted : July 17, 2012
Last Update Posted : June 3, 2015
Stanford University
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
The inter- and intra-variability in the pharmacokinetic parameters of different formulations and doses of simvastatin in healthy subjects and in subjects with celiac disease in remission will be evaluated. Additionally, baseline values of pharmacokinetic parameters of simvastatin for both study groups will be determined.

Condition or disease Intervention/treatment Phase
Celiac Disease Drug: Simvastatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase I, Randomized, Open Label, Mono-centered, Prospective Study to Evaluate the Pharmacokinetics of Different Formulations and Doses of Simvastatin in Healthy Subjects and in Subjects With Celiac Disease in Remission
Study Start Date : July 2012
Actual Primary Completion Date : July 2013
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Celiac Disease
Drug Information available for: Simvastatin

Arm Intervention/treatment
Experimental: Liquid formulation of Simvastatin Drug: Simvastatin
Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug

Active Comparator: Tablet formulation of Simvastatin Drug: Simvastatin
Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug

Primary Outcome Measures :
  1. Peak plasma concentration (Cmax) of simvastatin [ Time Frame: 0, 15, 30, 60, 90, 120, 180 minutes post-dose ]
    Determination of time-dependent concentrations of simvastatin in collected serum of each subject following oral administration of two different formulations and two different doses of simvastatin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • If the subject is female, she is eligible to enter and participate in this study if she is physiologically incapable of becoming pregnant or has a negative urine pregnancy test at screening and at baseline visit
  • Negative Serology for Hepatitis B/C, HIV
  • Non-OATP1B1*5 carriers
  • Negative Serology for anti-transglutaminase IgA antibody, and normal levels of total IgA
  • For subjects with celiac disease, also

    • Diagnosis of celiac disease confirmed by medical history, histological evaluation of small intestinal mucosa on small bowel biopsy, and abnormal anti-transglutaminase antibody titers
    • Followed a gluten-free diet for at least one year, as verified by normal anti-transglutaminase antibody levels, Marsh 0-1 score on a follow-up biopsy within the past 12 months, and absence of any clinical signs or symptoms of celiac disease observed at diagnosis

Exclusion criteria:

  • Current smoker or quit smoking less than 2 years ago
  • Female breastfeeding or disagrees to use an effective mechanical contraceptive method (e.g. diaphragm or nonhormonal intrauterine device in combination with preservative)
  • Presence of any known on-going disease which is judged to be relevant according to the investigator, besides celiac disease for the cohort of celiac patients in remission
  • State after operations of the stomach or bowel (exception: appendectomy)
  • Participation in any other clinical trial with investigational or approved drugs within the last month before the study
  • Regular alcohol consumption of more than 25 g / day
  • Use of any prescription or non-prescription drugs (including herbal supplements) must be discontinued 30 days prior to study (exceptions: paracetamol and NSAIDs, not taken longer than 2 days in a row and not taken within the last 3 days before the study)
  • Consumption of grapefruit, star fruit, grapefruit juice, or star fruit juice must be discontinued 7 days prior to the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01642862

Layout table for location information
University Hospital Zurich, University Hospital Zurich, Gastroenterology and Hepatology
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Stanford University
Layout table for investigator information
Principal Investigator: Gerhard Rogler, Prof MD PhD University Hospital Zurich, Gastroenterology and Hepatology
Layout table for additonal information
Responsible Party: University of Zurich Identifier: NCT01642862    
Other Study ID Numbers: CYPCEL-1103
First Posted: July 17, 2012    Key Record Dates
Last Update Posted: June 3, 2015
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors